ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

Abstract Number: 1757
Association of the Lupus Low Disease Activity State (LLDAS) with Health-Related Quality of Life
Abstract Number: 1758
Physical Activity and Sedentary Behaviour in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1759
Sleep Disturbance Is Associated with Worsening Patient-Reported Outcomes over Two Years in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1760
Systemic Lupus Erythematosus in Immigrants: Results from the 1000 Canadian Faces of Lupus Study
Abstract Number: 1761
Fatigue in Patients with Systemic Lupus Erythematosus Is Independent of Their Disease Activity but Dependent on Their Damage Accrual and Body Mass Index
Abstract Number: 1762
Systemic Lupus Erythematosus and the Evaluation of Poor Sleep
Abstract Number: 1763
Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus Following 7 Years of Treatment Exposure: Impact of Clinical Characteristics over Time
Abstract Number: 1764
Effect of Disease Remission on Organ Damage and Quality of Life in Chinese Patients with Systemic Lupus Erythematosus
Abstract Number: 1765
Minimal Clinically Important Differences for Generic Patient Reported Outcomes Tools in SLE
Abstract Number: 1766
Impact of Depression on SLE Flares
Abstract Number: 1767
Poor Body Image in Lupus: Is It Disease Activity, Damage, Sleep, Pain, Fatigue, Stress, Function, Medications, Depression or Fibromyalgia?
Abstract Number: 1768
Fatigue in SLE Is Associated with Neuropsychiatric Involvement, Pain, Impaired Sleep and a Reduced Quality of Life
Abstract Number: 1769
Fatigue in Anti-Nuclear Antibody Positive Individuals with Insufficient Criteria to Diagnose a Systemic Autoimmune Rheumatic Disease
Abstract Number: 1770
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
Abstract Number: 1771
Depression Is Associated with a Poorer with Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
Abstract Number: 1773
Risk Factors for Cerebrovascular Events in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
Abstract Number: 1774
Chronological Analysis of Damage Accrual in Patientes with Systemic Lupus Erythematosus: Results from the Spanish Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)
Abstract Number: 1775
Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus
Abstract Number: 1776
Analysis of Progressive Brain and Corpus Callosum Atrophy and Association with Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Abstract Number: 1777
The Accumulation of Organ Damage, Public Insurance Enrollment and Youth Are Associated with Increased Hospitalizations in a Population-Based Cohort of Lupus Patient
Abstract Number: 1778
Differences Between Early and Late Cardiovascular Disease in a Population-Based Cohort of Systemic Lupus Erythematosus Patients
Abstract Number: 1779
Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Abstract Number: 1780
Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 1781
Analysis of Influences of Various Factors on the Prognosis of Acute Confusional State of Diffuse Psychiatric/Neuropsychological Syndromes in Systemic Lupus Erythematosus
Abstract Number: 1782
Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease
Abstract Number: 1783
Phenome-Wide Association Study Identifies a New Association of Atrial Fibrillation in Males with Systemic Lupus Erythematosus
Abstract Number: 1784
The Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Lupus Erythematosus: A Population-Based Study
Abstract Number: 1785
Prevalence and Associated Factors of Low Bone Mass in Adults with Systemic Lupus Erythmatosus
Abstract Number: 1786
Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study
Abstract Number: 1787
Increased Heart Rate Variability Reflects Improvement in Clinical Status of Patients with Systemic Lupus Erythematosus
Abstract Number: 1788
Alterations in Sense of Smell and Limbic Structures in Patients with Systemic Lupus Erythematosus during 3-Years Follow-up
Abstract Number: 1789
Herpetic Viruses in Lupus
Abstract Number: 1790
Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Abstract Number: 1791
Loss of Elbow Hyperextension in Females with Early Rheumatologic Disease Was Common in Systemic Lupus Erythematosus and Rheumatoid Arthritis but Rare in Fibromyalgia
Abstract Number: 1792
Cardiac Surgery in Systemic Lupus Erythematosus Patients: Clinical Characteristics and Outcomes
Abstract Number: 1793
Visceral Adiposity Assessed By DXA in Juvenile-Onset Systemic Lupus Erythematosus: A Correlation with Damage Index and Disease Duration
Abstract Number: 1794
The High Disease Activity State Is an Adverse Prognostic Indicator in SLE and Defines a Clinically Distinct Population
Abstract Number: 1795
Four Years Follow-up of Subclinical Atherosclerosis in Systemic Lupus Erythematosus Patients
Abstract Number: 1796
Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 1797
Seasonal Differences in the Disease Onset and the Exacerbation of Systemic Lupus Erythematosus
Abstract Number: 1798
Risk Factors for Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review
Abstract Number: 1799
Smoking, Antiphospholipid Antibodies and Thrombosis in SLE
Abstract Number: 1800
Prevalence of ECG Cardiovascular Abnormalities in Lupus Patients: A Novel Approach Using 5 ECG Elements
Abstract Number: 1801
Clinical Implications of Persistent Sinus Tachycardia in Systemic Lupus Erythematous: A Retrospective Study
Abstract Number: 1802
Prevalence of CMV in the Ohio State University Lupus Population
Abstract Number: 1803
General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia
Abstract Number: 1804
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus:  a Single Centre Experience
Abstract Number: 1805
Factors Associated with Complete Remission in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study in One Center
Abstract Number: 1806
Adherence to Treatment and Social,  Educational Levels in Patients with Systemic Lupus Erythematosus
Abstract Number: 1807
Prevalence of Progressive Multifocal Leukoencephalopathy in Adults and Children with Systemic Lupus Erythematosus
Abstract Number: 1808
Frequency and Factors Associated with Thirty Day Hospital Readmissions Among Systemic Lupus Erythematosus Patients in a Community Hospital in the California Central Valley
Abstract Number: 1809
Influence of Solar Radiation in Cutaneous Manifestations of Lupus: Data from the Gladel Cohort
Abstract Number: 1810
Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth
Abstract Number: 1811
Systemic Lupus Erythematosus: Detailed Anatomy of a Cohort (follow-up for more than 35 years). 
Abstract Number: 1812
Impact of Severe Organic CNS Involvement in Cognitive Function in a Cohort of Systemic Lupus Erythematosus Patients
Abstract Number: 1813
Prevalence and Incidence of Systemic Lupus Erythematosus in Tucuman -Argentina
Abstract Number: 1814
Epidemiology and Microbiology of Pneumonia in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1815
Frequency and Predictors of Attaining the Lupus Low Disease Activity State (LLDAS) in a Multinational SLE Cohort from the Asia Pacific
Abstract Number: 1816
SLE and Uctd in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 1817
A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using a Multistate Markov Model Approach
Abstract Number: 1818
Predictors for Mortality in Hospitalized Patients with Systemic Lupus Erythematosus from 1999 to 2009: A Follow-up Multicenter Study in China
Abstract Number: 1819
Myocarditis in Systemic Lupus Erythematosus

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology